Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

An interim analysis of a randomized trial in triple-negative breast cancer comparing the addition of pembrolizumab to neoadjuvant chemotherapy with chemotherapy alone and adjuvant pembrolizumab with placebo after definitive surgery was reported after 39 months of follow-up. Event-free survival at 3...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-02, Vol.386 (6), p.556-567
Hauptverfasser:	Schmid, Peter, Cortes, Javier, Dent, Rebecca, Pusztai, Lajos, McArthur, Heather, Kümmel, Sherko, Bergh, Jonas, Denkert, Carsten, Park, Yeon Hee, Hui, Rina, Harbeck, Nadia, Takahashi, Masato, Untch, Michael, Fasching, Peter A, Cardoso, Fatima, Andersen, Jay, Patt, Debra, Danso, Michael, Ferreira, Marta, Mouret-Reynier, Marie-Ange, Im, Seock-Ah, Ahn, Jin-Hee, Gion, Maria, Baron-Hay, Sally, Boileau, Jean-François, Ding, Yu, Tryfonidis, Konstantinos, Aktan, Gursel, Karantza, Vassiliki, O’Shaughnessy, Joyce
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Cancer Cancer therapies Carboplatin Chemotherapy Chemotherapy, Adjuvant Committees Cyclophosphamide Doxorubicin Epirubicin Female Hematology Humans Immunotherapy Intention to Treat Analysis Invasiveness Kaplan-Meier Estimate Life Sciences Lymphatic system Medical prognosis Middle Aged Monoclonal antibodies Neoadjuvant Therapy Oncology Paclitaxel Patients Pembrolizumab Placebos Progression-Free Survival Radiation therapy Statistical analysis Surgery Survival Targeted cancer therapy Treatments in Oncology Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - surgery Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	An interim analysis of a randomized trial in triple-negative breast cancer comparing the addition of pembrolizumab to neoadjuvant chemotherapy with chemotherapy alone and adjuvant pembrolizumab with placebo after definitive surgery was reported after 39 months of follow-up. Event-free survival at 3 years was 84.5% in the pembrolizumab group and 76.8% in the group that did not receive pembrolizumab.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2112651